期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 125, 期 5, 页码 1901-1912出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI80142
关键词
-
资金
- Martin Delaney CARE Collaboratory
- Martin Delaney DARE Collaboratory [NIH AI096113, 1U19AI096109]
- amFAR [108931-56-RGRL]
- Johns Hopkins Center for AIDS Research, NIH [RO143222]
- Howard Hughes Medical Institute
- NIH [RO143222, DP5OD019851, F31AI116316]
Reversal of HIV-1 latency by small molecules is a potential cure strategy. This approach will likely require effective drug combinations to achieve high levels of latency reversal. Using resting CD4(+)T cells (rCD4s) from infected individuals, we developed an experimental and theoretical framework to identify effective latency-reversing agent (LRA) combinations. Utilizing ex vivo assays for intracellular HIV-1 mRNA and virion production, we compared 2-drug combinations of leading candidate LRAs and identified multiple combinations that effectively reverse latency. We showed that protein kinase C agonists in combination with bromodomain inhibitor JQ1 or histone deacetylase inhibitors robustly induce HIV-1 transcription and virus production when directly compared with maximum reactivation by T cell activation. Using the Bliss independence model to quantitate combined drug effects, we demonstrated that these combinations synergize to induce HIV-1 transcription. This robust latency reversal occurred without release of proinflammatory cytokines by rCD4s. To extend the clinical utility of our findings, we applied a mathematical model that estimates in vivo changes in plasma HIV-1 RNA from ex vivo measurements of virus production. Our study reconciles diverse findings from previous studies, establishes a quantitative experimental approach to evaluate combinatorial LRA efficacy, and presents a model to predict in vivo responses to LRAs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据